Approved SimpleScreen CRC Blood Test for Colorectal Cancer Screening
Abbott launched SimpleScreen CRC, an FDA-approved blood test for colorectal cancer screening, developed by Freenome. The test is for average-risk adults 45+ and is covered by Medicare. It detected 81.1% of cancers in trials. Abbott aims to expand screening options, with support services for patients.
How this was made
The 30-second read
Why it matters
The FDA approval could open a sizable unscreened population (≈60 million) to Abbott's services, but uptake depends on physician and patient acceptance.
Market read
A new FDA‑approved cancer screening test adds a potential growth driver for Abbott and may influence the broader diagnostics sector.
What to watch
Competition from established stool‑based tests and colonoscopy, as well as payer utilization management.
Background
Abbott's cancer diagnostics business previously offered stool‑based Cologuard Plus; the new blood test diversifies its screening portfolio.
Ticker impact
Abbott launched SimpleScreen CRC, an FDA‑approved blood test for colorectal cancer screening, commercialized exclusively by Abbott.
likely modest upside as investors price in incremental sales from the FDA‑approved test
First‑report FDA approval and commercial launch; market expects added revenue but scale is uncertain.
Market effects
Strengthens the diagnostics and cancer‑screening segment, may pressure peers without similar blood‑based offerings.
U.S. healthcare market sees a new Medicare‑covered screening option, potentially boosting Abbott's domestic sales.
Limited to U.S. due to Medicare coverage; foreign markets may follow if FDA approval is leveraged.
Counterpoint
The test may face adoption hurdles and reimbursement delays, limiting revenue impact.
Key entities
- CompanyAbbott Laboratories
US‑listed diagnostics and medical devices firm (ticker ABT).
- CompanyFreenome
Developer of the SimpleScreen CRC assay, partnered with Abbott for commercialization.
